A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
Clinical trial NCT01375842 · COMPLETED
Trial details
- NCT number
- NCT01375842
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-06-21
- Primary completion
- 2018-09-30
- Enrollment
- 661
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.